Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke

Noel Clarke a Consultant Urologist at Salford Royal Hospital presents in opposition of treating all patients with bone-targeted therapy during his portion of the debate on bone-targeted therapy with zoledronate or denosumab.

Access to all Advanced Prostate Cancer Consensus Conference Video Coverage

Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe